June 16th 2025
The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Roflumilast cream safe, effective for atopic dermatitis in children 6 years and up
November 16th 2022Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).
Frequent allergies in pediatric atopic dermatitis, eosinophilic esophagitis patients in Puerto Rico
November 16th 2022New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.
Pediatric patients with AD have an increased risk of type 2 inflammatory diseases
July 13th 2022A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.